A Civilization on the Line, an 8pm Deadline, and Apple Having a Very Bad Tuesday

Trump posted Tuesday morning that "a whole civilization will die tonight" if Iran does not reopen the Strait by 8pm, which is simultaneously the most dramatic thing a president has put on Truth Social and the reason your portfolio spent the day holding its breath.

Stocks fell modestly, Apple dragged the Dow lower on foldable iPhone concerns, and health insurers had a massive day on Medicare rate news. Today's Closing Bell has everything that moved before tonight's moment of truth.

As global tensions rise, one company is quietly supporting every branch of the U.S. military.

Army. Navy. Air Force. Marines.

That company is SpaceX.

But what most people don’t realize is that it may not stay private forever.

There’s growing speculation that Elon Musk could eventually bring it public in what could be one of the largest IPOs ever.

If that happens, early positioning could be critical.

Click here to see how some investors are preparing

Tuesday was one long countdown to Trump's 8pm deadline for Iran to reopen the Strait of Hormuz, with stocks falling modestly as negotiators privately said a deal by tonight was unlikely.

Apple was the session's biggest drag after Nikkei reported engineering setbacks on its foldable iPhone, while health insurers surged on a bigger-than-expected Medicare rate increase, and Broadcom climbed on new AI contracts with Google and Anthropic.

The VIX stayed elevated, and the market's message going into tonight is clear: it is not panicking, but it is not relaxed either.

Silo Pharma Inc (NASDAQ: SILO) just received notice that the European Patent Office intends to grant a patent for its stress-prevention therapy. The approach targets stress before it becomes a problem, rather than treating symptoms after they appear. The underlying technology is exclusively licensed from Columbia University.

For a small developmental-stage biotech, a major European patent is not just a legal milestone. It is the foundation on which everything else is built.

Prevention Over Treatment

Most stress and depression therapies work by managing symptoms after they start. Silo's approach is different. It aims to prevent the onset of stress-induced fear and depressive behavior in the first place.

That distinction matters. You can see why a prevention model could appeal to a very different patient population than traditional antidepressants. It opens up use cases that symptom-based treatments cannot reach.

Small Company, Wide Protection

Silo is tiny in biotech terms. But patents do not care about company size. This one covers major European markets, and the company is already evaluating broader protection across additional countries.

You rarely see a developmental company this small land a meaningful patent in a major market. It does not guarantee success, but it sure makes the path forward a lot more interesting.

Geospace Technologies (NASDAQ: GEOS) just cut about 20% of its global workforce as part of a restructuring plan to reduce costs and improve efficiency. On the surface, it sounds like a standard corporate move.

In reality, cuts this deep usually mean something more serious is happening under the hood.

This Is Not a Small Adjustment

A 20% reduction is not fine-tuning. It is a reset. Companies make moves like this when they believe their current cost structure no longer aligns with the realities of their business.

That could mean slower demand, tighter margins, or a shift in the company's direction. When you look at this, it feels less like optimization and more like correction.

Efficiency Comes With Trade-Offs

Yes, the company expects to save money. That part is clear. But cutting that many people also reduces capacity, slows execution, and can impact future growth if demand returns quickly. That balance is always tricky.

This is where your perspective matters: cost savings look good in the short term, but they can limit how quickly a company can bounce back.

Geospace operates in a space closely tied to energy and industrial demand, sectors that can shift quickly. A move like this suggests the company is preparing for a different environment ahead.

Not necessarily worse, but definitely more cautious.

While President Trump officially earns $400,000 per year, records show he’s collected up to $250,000 per month from another source.

Until recently, most Americans had no access to this type of investment.

But a new shift — tied to Executive Order 14330 — has started to open the door.

Now, investors interested in early-stage and disruptive opportunities are taking a closer look.

See how to access it

TransDigm Group (NYSE: TDG) just closed a $2.2 billion cash deal to acquire Jet Parts Engineering and Victor Sierra Aviation Holdings. Both companies specialize in aftermarket aerospace parts. That means the components, airlines, and maintenance providers need to keep planes flying long after they leave the factory. Together, they generated roughly $280 million in revenue last year.

TransDigm does not make headlines like Boeing or Airbus. But quietly, it might be running the smartest business model in the entire industry.

The Aftermarket Is Where the Money Lives

Building an airplane is brutal. Margins are thin, timelines are long, and contracts get renegotiated endlessly. But every plane that flies needs replacement parts for decades. That aftermarket business is high margin, recurring, and nearly impossible to disrupt.

TransDigm has built its entire company around that reality. You follow where the profit pools actually sit in aerospace, and they are not in making new jets. They are keeping the old ones flying.

The Acquisition Machine Keeps Running

Every new proprietary part TransDigm adds to its portfolio is another captive revenue stream. Your airline cannot easily switch suppliers when the part needed is only made by one company.

TransDigm has built its empire by buying aerospace parts companies one after another and integrating them into a highly efficient operating model. You watch a company execute the same playbook repeatedly for years with consistent results, and it stops being a coincidence.

TransDigm is not just growing. It is compounding through a strategy that few competitors have figured out how to match.

👉 Click here to get our closing report to your cell for free!

LanzaTech [LNZA] $27.52 (+52.85%)

LanzaTech reported Q4 2025 adjusted EBITDA of $2.4 million versus a loss of $21.2 million a year ago, marking a dramatic financial turnaround for the carbon recycling company.

The earnings flip, combined with the EPA's ethanol waiver announcement this week, which directly benefits LanzaTech's sustainable fuels business, gave investors two separate reasons to reprice the stock in a single session.

Avis Budget Group [CAR] $255.15 (+20.01%)

Avis has been caught in a short squeeze that has sent shares up over 100% in a month, fueled by airport chaos from TSA staffing cuts driving travelers to car rentals, and a tiny float of only 13 million shares creating explosive upside pressure.

Tuesday's move is a continuation of that squeeze, with options activity and retail momentum piling in despite Deutsche Bank downgrading the stock and analysts setting price targets well below where it trades.

Alignment Healthcare [ALHC] $21.74 (+16.44%)

The Trump administration finalized Medicare Advantage payment rates for 2027 at a 2.48% increase plus an additional 2.5% risk adjustment uplift, a dramatic reversal from the 0.09% initially proposed in January that had crushed the entire sector.

Alignment, which runs Medicare Advantage plans across five states, is one of the most direct beneficiaries of a higher payment rate, and the market repriced that immediately.

Geospace Technologies [GEOS] $9.82 (-21.21%)

Geospace has been in a sustained revenue decline since its Q1 2026 results in February showed a 31% year-over-year revenue drop, with its Energy Solutions segment down 40% due to lower utilization of its OBX seismic rental fleet.

Tuesday's continued selling reflects investors reassessing whether the company's exposure to oilfield services makes it a beneficiary or a casualty of the Iran war's energy disruption, with the answer so far leaning toward the latter.

Pulse Biosciences [PLSE] $19.96 (-12.99%)

Pulse Biosciences reported Q4 earnings that missed on revenue and pushed back the commercial timeline for its CellFX pulsed electric field platform, which uses nanosecond pulses of electrical energy to treat skin conditions and cancer applications

There was genuine institutional ownership going into this print, and the 1.84x relative volume signals the exit was deliberate rather than panicked.

Merlin [MRLN] $6.30 (-8.96%)

Merlin is an AI-powered autonomous flight company that went public via SPAC on March 17 and dropped 61% on its debut day, and has been struggling to rebuild investor confidence ever since.

The stock continues to drift lower as the market digests its auditor's going concern warning, its $5 million monthly cash burn rate, and the significant share dilution that came with the SPAC transaction, with no new contract news to change the narrative.

Oil prices are on the rise, putting the energy sector back in the spotlight.

Large banks have raised their crude outlooks, and investors are reexamining which companies could benefit most if supply risks persist.

In a new report, Zacks highlights three oil stocks standing out in the current market backdrop.

[View the briefing]

*The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors and may represent the partial close of a position. Access grants you a comprehensive list of all open and closed trades.
*This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service".

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.